GlaxoSmithKline sales and marketing update

Late last year, GlaxoSmithKline launched Nucala mepolizumab in the U.S. to treat severe eosinophilic asthma in patients at least 12 years old. The wholesale acquisition cost (WAC) is $2,500 per 100 m...